ArticleOpen forum infectious diseases2026
Perspectives on PrEP/PEP Integration in Telehealth Gender-Affirming Care: A Survey of Clients From a National Telehealth Platform.
Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Background: Transgender individuals face disproportionate HIV burden yet experience significant barriers to accessing biomedical HIV prevention. We assessed awareness, experience, and willingness among trans adults to use pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) when integrated with telehealth-delivered gender-affirming hormone care (GAC). Methods: We conducted a cross-sectional survey of clients receiving GAHC via a national subscription-based telehealth platform between October 2023 and January 2024. Using stratified sampling to ensure inclusion of transgender men (TGM) and those residing in rural areas, we assessed PrEP/PEP awareness, prior use, barriers, and willingness to use these services if recommended by their GAC provider. Multivariable logistic regression identified factors associated with stated willingness (yes/no). Results: Among 387 respondents (from 2506 survey invitations, 15.4% response rate), 54.8% identified as transgender women (TGW), 45% were between the ages of 18 and 25, and 74% identified as white, and 13% resided in rural areas. Pre-exposure prophylaxis awareness was moderate among TGW (56%) and TGM (69%), while PEP awareness was 24% among TGW and 31% among TGM. Only 2% of TGW were using PrEP (0% of TGM), and 0% had used PEP. Despite limited prior utilization, 67% expressed willingness to use PrEP and 66% willingness to use PEP if recommended by their GAC provider. Public insurance (vs private) and self-reported HIV worry (vs not worried) were associated with willingness to use both PrEP (public insurance: aOR 3.64, Conclusions: Among clients of a subscription-based telehealth platform, stated acceptability of integrated PrEP/PEP services was high regardless of gender identity or geography. Limited awareness, cost concerns, and the large gap between awareness and utilization require further attention to realize the potential benefits of biomedical HIV prevention integration into telehealth GAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.